On February 26, 2014, the European Parliament approved the revised Tobacco Products Directive (the Revised Directive ), which governs the manufacture, presentation and sale of tobacco and related products in the European Union. This Revised Directive was passed by the European Parliament more than ten years after approval of the Tobacco Products Directive (the Directive ). Prior to approval by the European Parliament, the Revised Directive was recommended by the European Union Member States. The Revised Directive will now be reviewed by the European Council, and is scheduled to take effect in 2016.

With an overall effort to limit the appeal of tobacco products, the Revised Directive regulates various areas, including labeling, remote sales and disclosure of ingredients. In particular, the scope of the Revised Directive is broader than the Directive, covering electronic cigarettes.

Electronic cigarettes that contain nicotine, and that are not for medicinal purposes, are covered by the Revised Directive. However, electronic cigarettes that do not contain nicotine are not covered by the Revised Directive.

For those electronic cigarettes covered by the Revised Directive, manufacturers will be required to report annually, to the various Member States, the sales volume of the products as well as the types of users, user preferences and trends. Manufacturers must notify Member States of the ingredients used in their products. There will also be limitations on advertising. The Revised Directive also mandates that health warnings appear on the packaging of electronic cigarettes. There will be a cap on the maximum nicotine concentration level for electronic cigarettes as well as a cap on the maximum volumes for cartridges.

For questions and/or comments, please contact Bryan Haynes, Troutman Sanders practice partner, at 804.697.1420 or by email.

E-cigarettes and the eu – a freedom of information request to medicines and healthcare products regulatory agency – whatdotheyknow

Cheap e-cigarettes – best electronic cigarette online sale – free shipping

Dear Enquirer,

Thank you for your enquiry to the Medicines and Healthcare Products
Regulatory Agency. This automated response confirms that we have received
your email and that it will be dealt with as quickly as possible.

You can expect a reply from us within a few days for a straightforward
request, however where a more detailed response or contribution from a
specialist is required this is likely to take longer we endeavour to
respond to all requests within the Department of Health s target response
time of 18 working days. Further information on how we handle different
requests can be found on our website at the link below

1

Our website contains a wealth of information which may assist with your
enquiry. Some of our popular pages are

Clinical Trials of medicines

2

Clinical Trials of medical devices

3

Manufacturer s and wholesale dealer s licences

4

Registration of medical devices, opticians and dental laboratories

5

Reporting a side effect to a medicine

6

Reporting an adverse incident involving a medical device

7

Does my product need a licence?

8

Reporting a counterfeit medical product

9

Buying medicines over the internet

10

If you have not heard from us after 18 working days then please contact us
on 020 3080 6000.

Kind regards

Customer Services
External Relations
Medicines and Healthcare Products Regulatory Agency

Please note this is an automated reply please do not respond to this
message.

This email and any files transmitted with it are confidential. If you are
not the intended recipient, any reading, printing, storage, disclosure,
copying or any other action taken in respect of this email is prohibited
and may be unlawful.

If you are not the intended recipient, please notify the sender
immediately by using the reply function and then permanently delete what
you have and outgoing email messages are routinely
monitored for compliance with the Department of Healths policy on the use
of electronic communications.

For more information on the Department of Healths email policy, click

show quoted sections

Communications via the GSi may be automatically logged, monitored and/or
recorded for legal purposes.

References

Visible links
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.